Back to News
Sep 17, 2025 4:00 PM

Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials

Johnson & Johnson (NYSE:JNJ) and Protagonist Therapeutics Inc. (NASDAQ:PTGX) on Wednesday released new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies of icotrokinra compared to deucravacitinib in patients with moderate-to-severe plaque psoriasis.

Icotrokinra met both co-primary endpoints compared to placebo at Week 16 with similar adverse event rates and showed superiority to Bristol-Myers Squibb & Co.’s (NYSE:BMY) Sotyktu (deucravacitinib) at multiple timepoints in adult patients.

Icotrokinra showed superior skin clearance vs placebo (Week 16) and deucravacitinib (Weeks 16 and ...